MarketIntelligenceCenter.com (Free subscription) | yesterday
GlaxoSmithKline PLC (NYSE: GSK) hit a new 52-Week high of $42.70 so far today. Currently the stock is up $1.12 (2.7%) to $42.65 on 852,101 shares traded. Today's high is up $15.50 from a 52-Week Low of $27.15. GlaxoSmithKline PLC stock has been showing support around $40.72 and resistance in the $41.96 range. Technic...
Rocky Mount Telegram - Business (Free subscription) | yesterday
TRENTON, N.J. — British drugmaker GlaxoSmithKline PLC said Monday it is temporarily withdrawin...
San Fransisco Chronicle (Free subscription) | yesterday
British drugmaker GlaxoSmithKline PLC says it's withdrawing its application for U.S. approval of a drug to prevent prostate cancer. The drug is already sold under the name Avodart, for treating symptoms of an enlarged prostate. The company was seeking... Cancer - Prostate cancer - Health - Conditions and Diseases - Prostate
Avian Flu Diary (Free subscription) | yesterday
# 4066 GlaxoSmithKline, makers of the Arepanrix vaccine, have ordered doctors to hold off giving any more doses from one particular batch while the company investigates a higher than normal number of allergic reactions. The number of doses on hold are about 170,000 – a fraction of the 7.5 million doses already delivered to Canada. Six cases of anaphylaxis from this batch were reported in Manitoba,...
Miami Herald (Free subscription) | yesterday
British drugmaker GlaxoSmithKline PLC said Monday it is temporarily withdrawing its application for U.S. approval of a drug to prevent prostate cancer.
Market Watch (Free subscription) | 11/18/2009
BOSTON (MarketWatch) -- Vivus Inc. early Wednesday reported positive Phase III clinical results for its new drug avanafil for the treatment of erectile dysfunction, or ED. "These Phase III avanafil data not only confirm the robust efficacy we've seen in earlier trials, but potentially differentiate avanafil from other PDE5 inhibitors when it comes to side effects and time-to-onset of efficacy,"...
Joseph Kim, MD, MPH (Free subscription) | 11/17/2009
The FDA approved the fifth vaccine for protection against the 2009 H1N1 influenza virus. The vaccine is manufactured by ID Biomedical Corp. of Quebec, Canada, owned by GlaxoSmithKline PLC. So, here's a list of the current injectable H1N1 vaccines: Influenza A (H1N1) 2009 Monovalent Vaccine (CSL Limited) Influenza A (H1N1) 2009 Monovalent Vaccine (ID Biomedical Corporation of Quebec) Influenza A (H1N1)...
Medical News Today (Free subscription) | 11/17/2009
The U.S. Food and Drug Administration announced that it has approved a fifth vaccine for protection against the 2009 H1N1 influenza virus. The vaccine is manufactured by ID Biomedical Corp. of Quebec, Canada, owned by GlaxoSmithKline PLC. As with the four previous H1N1 influenza vaccines licensed by the FDA on Sept.
Seattle Times (Free subscription) | 11/16/2009
GlaxoSmithKline PLC and Nabi Biopharmaceuticals said Monday they will work together to develop vaccines to help smokers give up the habit, in a deal that could be worth more than $500 million.
Business Wire (Free subscription) | 11/13/2009
CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Hewlett Packard Company (NYSE: HPQ), 3Com Corporation (Nasdaq: COMS), Cisco Systems Inc. (Nasdaq: CSCO), Wal-Mart Stores Inc. (NYSE: WMT)...
MarketIntelligenceCenter.com (Free subscription) | 11/12/2009
GlaxoSmithKline PLC (NYSE: GSK) opened at $41.77. So far today, the stock has hit a low of $41.44 and a high of $41.80. GSK is now trading at $41.57, up $0.34 (0.82%). The stock hit its 52-Week high of $42.18 last month and set its 52-Week low of $27.15 in March. GSK is trading higher today on news that has the company has received approval by U.S. regulato...
Miami Herald (Free subscription) | 11/11/2009
In a Nov. 9 story and headline about a Food and Drug Administration review of a drug being developed by XenoPort Inc. and GlaxoSmithKline PLC, The Associated Press reported erroneously on the nature of the FDA review. The FDA is considering an application for the drug in restless legs syndrome, not neuropathic pain.
San Fransisco Chronicle (Free subscription) | 11/11/2009
In a Nov. 9 story and headline about a Food and Drug Administration review of a drug being developed by XenoPort Inc. and GlaxoSmithKline PLC, The Associated Press reported erroneously on the nature of the FDA review. The FDA is considering an application for... Food and Drug Administration - GlaxoSmithKline - Associated Press - Health - United States
Seattle Times (Free subscription) | 11/11/2009
In a Nov. 9 story and headline about a Food and Drug Administration review of a drug being developed by XenoPort Inc. and GlaxoSmithKline PLC, The Associated Press reported erroneously on the nature of the FDA review. The FDA is considering an application for the drug in restless legs syndrome, not neuropathic pain.
Philadelphia Inquirer (Free subscription) | 11/11/2009
GlaxoSmithKline P.L.C. today said the federal Food and Drug Administration approved its H1N1 flu vaccine for use in the United States.
The 3 latest articles published by users on GlaxoSmithKline plc :
tamilselvan1 | 08/16/2009
Drugmaker GlaxoSmithKline PLC said Friday it has started testing its swine flu vaccine in humans. Glaxo said it plans to conduct 16 clinical trials of its swine flu vaccine in more than 9,000 people in Europe and North America.
aarkstore | 08/05/2009
Introduction This databook is a detailed information resource covering all the key data points on Oral hygiene in South Africa. It includes comprehensive value volume segmentation and market share data. The databook supplies actual data to 2007 and full forecasts to 2012. Scope * Contains information on 5 categories: Toothpaste, Toothbrushes, Mouthwash, Dental floss and Denture care * Provides market...
aarkstore | 08/05/2009
Introduction This databook is a detailed information resource covering all the key data points on Oral hygiene in Finland. It includes comprehensive value volume segmentation and market share data. The databook supplies actual data to 2007 and full forecasts to 2012. Scope * Contains information on 5 categories: Toothpaste, Toothbrushes, Mouthwash, Dental floss and Denture care * Provides market value,...
Videos